Repeated adjuvant anti‐CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long‐term efficacy results of a prospective phase 2 study - Concepedia

Concepedia

Publication | Closed Access

Repeated adjuvant anti‐CEA radioimmunotherapy after resection of colorectal liver metastases: Safety, feasibility, and long‐term efficacy results of a prospective phase 2 study

39

Citations

32

References

2016

Year

Carsten‐O. Sahlmann, Kia Homayounfar, M. Niessner, Jerzy Dyczkowski, Lena‐Christin Conradi, Friederike Braulke, Birgit Meller, Tim Beißbarth, Β. Michael Ghadimi, J. Meller,

Abstract

Repeated RIT with <sup>131</sup> I-labetuzumab is feasible but is associated with hematotoxicity. Survival is very encouraging, especially for "truly adjuvant" patients. However, the maximum safe dose of <sup>131</sup> I-labetuzumab is a single administration of 50 millicuries/m<sup>2</sup> . Cancer 2017;123:638-649. © 2016 American Cancer Society.

References

	Year	Citations

Page 1